Treatment of Early Aggressive Rheumatoid Arthritis (TEAR)

• Status: Completed
• Trial end date: 2009-06-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to 1)to determine if it is better to treat all early RA patients with methotrexate in combination with hydroxychloroquine plus sulfasalazine or in combination with etanercept or reserve this treatment for patients who do not appropriately respond to methotrexate alone and 2) to determine which combination of methotrexate therapy is better

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Alabama at Birmingham
• Collaborators: Amgen; Barr Laboratories; Pfizer
• Treatments: Etanercept; Hydroxychloroquine; Methotrexate; Sulfasalazine

Criteria

Inclusion Criteria:

• Have a diagnosis of RA for less than or equal to 3 years

• Be 18 years of age or older at the time of diagnosis

Exclusion Criteria:

• Pregnant or lactating women

• History of chronic infection, such as hepatitis, pneumonia, or chronic skin infections

• Active TB or evidence of latent TB